Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Delivra Health BrandsDHBUF +12.11% 10-Year RORE % is 19.67 as of Mar. 2026. The stock has 3 warning signs investors should review. Among 670 Drug Manufacturers companies, Delivra Health Brands ranks better than 78.06% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Delivra Health Brands's 10-Year RORE % for the quarter that ended in Mar. 2026 was 19.67%.
The industry rank for Delivra Health Brands's 10-Year RORE % or its related term are showing as below:
DHBUF's 10-Year RORE % is ranked better than 78.06% of 670
companies
in the Drug Manufacturers industry
Industry Median: 6.47
vs DHBUF: 19.67
Delivra Health Brands (OTCPK:DHBUF) 10-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Delivra Health Brands 10-Year RORE % Related Terms
Delivra Health Brands 10-Year RORE % Historical Data
* Premium members only.
The historical data trend for Delivra Health Brands's 10-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Delivra Health Brands's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Delivra Health Brands 10-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Delivra Health Brands's 10-Year RORE % distribution charts can be found below:
* The bar in red indicates where Delivra Health Brands's 10-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 10-year before.
Delivra Health Brands (DHBUF) has a 10-Year RORE % of 19.67 as of Mar. 2026. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Delivra Health Brands and its competitors. According to the industry distribution chart, Delivra Health Brands ranks #147 out of 670 companies in the Drug Manufacturers industry, placing it in the top 21.9%.
Is Delivra Health Brands' 10-Year RORE % too high?
Delivra Health Brands' current 10-Year RORE % is 19.67. The Drug Manufacturers industry median 10-Year RORE % is 6.47. Delivra Health Brands' value of 19.67 is 204% above this industry median. Based on the distribution chart, Delivra Health Brands ranks #147 out of 670 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Delivra Health Brands' 10-Year RORE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Delivra Health Brands ranks #147 out of 670 companies for 10-Year RORE %. This places Delivra Health Brands in the top 22% of its industry — outperforming the majority of peers. The industry median 10-Year RORE % is 6.47. Delivra Health Brands' value of 19.67 is 204% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Drug Manufacturers company?
The median 10-Year RORE % among Drug Manufacturers companies is 6.47, based on 670 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Delivra Health Brands's current 10-Year RORE % of 19.67 is 204% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Delivra Health Brands and its competitors. For the Drug Manufacturers industry, the median 10-Year RORE % is 6.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Delivra Health Brands's current 10-Year RORE % is 19.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Delivra Health Brands stock overvalued right now?
Based on GuruFocus' analysis, Delivra Health Brands (DHBUF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.18, compared to a current price of $0.07 — trading 59% below its estimated fair value. The current 10-Year RORE % is 19.67 and 204% above the Drug Manufacturers industry median of 6.47. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For Delivra Health Brands (DHBUF), the current 10-Year RORE % is 19.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Delivra Health Brands Inc helping people take control of health with alternative wellness solutions. Its portfolio features brands like Dream Water and LivRelief that deliver relief from common, everyday issues like chronic pain, anxiety, and sleeplessness. The principal activities of the company are to provide lifestyle and health and wellness products to consumers and patients in regulated markets. The company geographically operates in Canada and United States, out of which it generates maximum revenue from Unites States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHBUF has been successfully added to your 
